Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Garg on the Need for Novel Imaging Techniques in nmCRPC

September 1st 2021

Natasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Ward on the Benefits of Delaying Salvage Therapy in Prostate Cancer

August 31st 2021

Matthew C. Ward, MD, discusses the benefits of delaying salvage therapy in prostate cancer.

Black Men 97% Less Likely Than White Men to Receive Prostatectomy During COVID-19 Pandemic

August 31st 2021

During the height of the COVID-19 pandemic, Black patients were significantly less likely to undergo prostate cancer surgery compared with White patients, highlighting potential systemic inequities in care across medical specialties, and providing further rationale to recognize and the unintended diversion in cancer care due to the pandemic.

PARP Inhibitors Play Key Role in Prostate Cancer Paradigm, as Hunt for Biomarkers Continues

August 31st 2021

Wassim Abida, MD, PhD, discusses the role of PARP inhibition in the treatment of patients with prostate cancer, and the importance of biomarkers in guiding treatment decisions with these agents

Dr. Lyou on Key Takeaways from the ENZAMET Trial in Metastatic Prostate Cancer

August 31st 2021

Yung Lyou, MD, PhD, discusses the key takeaways from the phase 3 ENZAMET trial in metastatic prostate cancer.

Dr. Dorff on Biomarkers of Response to PARP Inhibitors in Prostate Cancer

August 30th 2021

Tanya B. Dorff, MD, discusses biomarkers of response to PARP inhibitors under investigation in prostate cancer.

Dr. Lyou on the Efficacy of ADT Plus Docetaxel in High-Volume mHSPC

August 30th 2021

Yung Lyou, MD, PhD, discusses the efficacy of androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.

Dr. Zhang on the State of Risk Stratification in mCRPC

August 30th 2021

Jingsong Zhang, MD, PhD, discusses the current state of risk stratification in metastatic castration-resistant prostate cancer.

External-Beam Radiation Plus Androgen Suppression Improves EFS, DFS Only in Intermediate-Risk Prostate Cancer

August 27th 2021

Six-months of adjuvant androgen suppression plus 74 Gy or 78 Gy of concurrent external-beam radiation led to a statistically significant improvement in event-free survival and disease-free survival but failed to improve distant metastasis-free survival and overall survival vs external-beam radiation alone in patients with intermediate-risk prostate cancer.

Dr. Abida on Future Research Directions in mCRPC

August 26th 2021

Wassim Abida, MD, PhD, discusses future research directions in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Garg on the Emergence of Antiandrogen Agents in nmCRPC

August 25th 2021

Natasha Garg, DO, discusses the emergence of antiandrogen agents in the nonmetastatic castration-resistant prostate cancer treatment paradigm.

Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate Cancer

August 24th 2021

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

Dr. Agarwal on the Efficacy of Intensified ADT in mHSPC

August 24th 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

Dr. Slovin on Selecting Among Available Treatment Options in mCSPC

August 24th 2021

Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.

Dr. Shore on the Utility of PSMA PET Imaging Agent Piflufolastat F 18 for Prostate Cancer

August 23rd 2021

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the clinical utility of piflufolastat F 18 in identifying suspected metastasis or recurrence of prostate cancer.

Dr. Tagawa on the Integration of PSMA-Targeted Agents in Prostate Cancer

August 23rd 2021

Scott Tagawa, MD, MS, FACP, discuss the integration of targeted agents in prostate cancer.

Dr. Morris on Findings From the TheraP Study in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses findings from the phase 2 TheraP study, and how they led to the development of the phase 3 VISION trial in metastatic castration-resistant prostate cancer.

Dr. Burgess on the Integration of PARP Inhibitors in Prostate Cancer

August 19th 2021

Earle Burgess, MD, discusses the integration of PARP inhibitors in advanced prostate cancer.

Novel Compound Looks to Shake Up mCRPC Treatment Landscape

August 19th 2021

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

Dr. Abida on Data from the PROfound Study in mCRPC

August 19th 2021

Wassim Abida, MD, PhD, discusses data from the phase 3 , PROfound trial in patients with metastatic castration-resistant prostate cancer.